. There is a limited body of work on the antiglycative function of (poly)phenols, relying on supra-physiological concentrations and use of non-bioavailable compounds (3, 4) . To inform the design of a physiologically relevant in-vitro study, a systematic literature review of dietary interventions quantifying plasma phenolic acids was carried out, to inform selection of physiologically relevant concentrations. Bovine Serum Albumin (BSA), either native (no treatment), pre-oxidised (incubated with 10nM H 2 O 2 , 22 for 8 hours) or incubated with a phenolic acid mixture, for 8 hours) was glycated. Glycation was carried out with i) glucose only (0, 5, or 10 mM), ii) glucose (0, 5, or 10 mM) plus H2O2 (10 nM), or iii) glucose (0, 5, or 10 mM) plus phenolic acids (10-160 nM). Fructosamine was measured using the nitroblue tetrazolium method. Following (high) dietary polyphenol intake, 3-hydroxyphenylacetic acid is the most abundant phenolic acid in peripheral blood (up to 338 μM) with concentrations for other phenolic acids ranging from 13 nM-200 μM. Presence of six phenolic acids with BSA during in-vitro glycation did not lower fructosamine formation. However, when BSA was pre-incubated with phenolic acids, significantly lower concentration of fructosamine was detected under glycoxidative conditions (glucose 5 or 10 mM plus H2O2 10 nM) (p < 0·001 vs. native BSA). Protein pre-treatment, either with oxidants or phenolic acids, is an important regulator of subsequent glycation in a physiologically relevant system. High quality in-vitro studies under conditions closer to physiology are feasible and should be employed by default.
